Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
90
Trial Sponsor
Clinical Trial Start Date
2007
0Primary Completion Date
2007
0Study Completion Date
2010
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 20
Phase 10
Official Name
Phase I/II Clinical Trial on Thymosin Alfa 1 of Allogeneic Hematopoietic Transplantation0
Last Updated
December 24, 2007
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
Thymosin alpha 10
Study summary
The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with hematological undergone allogenic bone marrow transplantation and CMV positive. The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the infection complications.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
